Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
05 mars 2024 16h35 HE
|
Mural Oncology, Inc.
DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 mars 2024 16h15 HE
|
Mural Oncology, Inc.
DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein...
Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference
27 févr. 2024 07h00 HE
|
Mural Oncology, Inc.
DUBLIN, Ireland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 févr. 2024 16h30 HE
|
Mural Oncology, Inc.
DUBLIN, Ireland, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein...
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
08 janv. 2024 07h00 HE
|
Mural Oncology, Inc.
Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful dataMural intends to nominate development...
Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies
15 nov. 2023 07h00 HE
|
Mural Oncology, Inc.
Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies